Kura Oncology stock rises on CEO insider purchase
Kura Oncology Inc (NASDAQ:KURA) shares experienced a 5.4% increase in after-hours trading on Monday following an insider stock purchase made by the company’s President and CEO, Troy Edward Wilson. The acquisition by Wilson, who serves in multiple roles including President, CEO, and a director, totaled 100,000 shares of common stock.
Wilson’s transaction, documented in a Form 4 filing with the Securities and Exchange Commission, took place on August 17, 2026, at a weighted average price of $11.12 per share, with trades ranging from $10.87 to $11.31. As a result of his purchase, Wilson now indirectly owns a total of 1,114,650 shares through various trusts, including the One Fish Two Fish Revocable Trust, the Lorax Charitable Remainder Unitrust, and direct holdings of 435,456 shares.
The value of his stock purchase amounted to approximately $1.1 million, signaling a substantial investment by the company’s top executive. Insider stock purchases are generally viewed as a positive indicator by market participants, as executives typically possess detailed knowledge about their company’s operations and future prospects.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
